Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Nerve block before bypass may stop Post-Surgery heart flutter

NCT ID NCT07271615

Symptom relief Sponsor: Xijing Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 05, 2026 · Updated 2 times

Summary

This study tests whether giving a nerve block (stellate ganglion block) before coronary artery bypass grafting (CABG) can reduce the chance of developing atrial fibrillation, a common irregular heartbeat after surgery. About 60 adults having CABG will be randomly assigned to receive the block or not. The goal is to see if this simple procedure can prevent a frequent complication and reduce the need for extra heart medications.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

60 people

The number who actually took part.

Started

Nov 2025

Finished

Jul 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * more than 18 years old * undergoing CABG * Provide informed consent Exclusion Criteria: * History of prior cardiac surgery or atrial fibrillation ablation; * Emergency coronary artery bypass grafting (CABG); * Concomitant cardiac procedures (e.g., congenital heart disease repair, left ventricular reconstruction, valve surgery, or aortic surgery); * Critical preoperative status requiring mechanical or pharmacological support before CABG; * Left ventricular ejection fraction (LVEF) \<35%; * History of atrial fibrillation (defined as a supraventricular tachyarrhythmia characterized by rapid and irregular atrial electrical activity); * Significant mitral valve disease (mitral valve area \<1.5 cm² or regurgitant jet area \<4 cm²), significant aortic valve disease (valve area \<1.5 cm² or regurgitant jet-to-left ventricular outflow tract ratio \>25%); * Severe left atrial enlargement (left atrial anteroposterior diameter \>55 mm); * Poorly controlled hyperthyroidism; * Conditions requiring radiotherapy, chemotherapy, or long-term hormonal therapy; * Patients with known clinical contraindications to stellate ganglion block (SGB).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Adult patients undergoing cabg are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

coronary artery disorder atrial fibrillation prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Adult patients undergoing cabg

Contacts and locations

Locations

  • Xijing Hospital

    Xi'an, Shaanxi, 710032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.